#Global Trends – Page 17 – HEALTHCARE INSIGHTS

Key Development On August 26, 2026, clinical-stage biopharmaceutical innovator Biohaven Ltd. (NYSE: BHVN) announced a definitive worldwide licensing agreement transferring... Read more

Tag: #Global Trends

MedTech Cybersecurity & Supply Chain Disruption: Boston Scientific Discloses Cyber Incident Impacting Global Order Processing and Shipments – Wall Street Models Up to 700 bps Q3 Revenue Exposure

Asia-Pacific Cardiometabolic Expansion: China NMPA Accepts Novo Nordisk’s Marketing Authorization Application for Oral Wegovy® (Semaglutide) to Contest Eli Lilly in $4.5 Billion Market

Neuroscience Licensing & Capital De-Risking: Biohaven Monetizes Lead Focal Epilepsy Candidate Opakalim (Kv7 Platform) to SK Biopharmaceuticals in $795 Million Strategic Divestment

Health Economics & Real-World Outcomes: Sustained Zepbound® (Tirzepatide) Use Associated with Up to 38% Reduction in Monthly Healthcare Costs Among Older Adults with Obesity After 12 Months

Precision Oncology Milestone: US FDA Approves Revolution Medicines’ Rasonque® (Daraxonrasib) as First-in-Class RAS(ON) Multiselective Inhibitor for Metastatic Pancreatic Cancer, Doubling Overall Survival to 13.2 Months

FDA EXPANDS IMAAVY: J&J TURNS FCRN BLOCKADE INTO A RARE AUTOIMMUNE GROWTH PLATFORM

ROCHE–ELI LILLY BRINGS ALZHEIMER’S BLOOD TESTING INTO MAINSTREAM DIAGNOSTIC INFRASTRUCTURE: COMPETITION IS SHIFTING FROM DRUGS TO ECOSYSTEMS

Non-Incretin Cardiometabolic Licensing: Genentech Pays $190 Million Upfront in $2.3 Billion Global License Agreement with Hanmi Pharm for Muscle-Preserving Obesity Peptide HM17321

Biologics & ADC CDMO Consolidation: Piramal Pharma Acquires Controlling 74% Stake in Yapan Bio for $7.95 Million – Accelerating Integrated ADCelerate™ Bioconjugation Platform

Facebook

Map

Online Members